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Abstract
Since the first cord blood transplantation (CBT), many indications have been proven for
this stem cell therapy. Besides the standard hematological indications, such as leukemia,
lymphomas, and aplastic anemia, CBT has also been a proven curative therapy for non-
hematological indications such as Krabbe’s disease, and osteopetrosis. As transplant-
related mortality (TRM), overall survival (OS) and disease-free survival (DFS) for CBT
continue to improve with larger inventories, double CBT, higher cell dose CB products,
optimal conditioning, GvHD, HLA matching, and infection prophylaxis and treatment,
the utility of this stem cell source will expand to certain indications which in the past,
rarely used CBT. For patients and physicians to accept CBT for indications such as
thalassemia, autoimmune diseases or HIV, the benefit-risk ratio has to be significantly
improved so that patients will take a chance on a risky procedure in order to improve
their lifespan or quality of life. We review here some of the efforts to improve clinical
outcome of CBT for thalassemia through increasing cell dosage using a combination
strategy – (1) Chow’s MaxCell second and third generation technologies that maximize
CB cell dosage, (2) double CBT, (3) no-wash thaw direct infusion advocated by Chow
et al., and (4) optimal product selection.
Keywords: unrelated donor cord blood transplantation, thalassemia cure, HIV cure,
autoimmune diseases cure, cord blood banking, cord blood processing, cord blood
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1. Introduction
Like other forms of hematopoietic stem cell transplantation (HSCT), unrelated donor cord
blood transplantation (CBT) is a lifesaving therapy capable of curing many diseases, including
∼80 standard hematologic and certain nonhematologic indications, such as thalassemia major.
In addition, HIV infection and ∼80 autoimmune diseases may be curable with unrelated donor
CBT as well [1]. Unlike adult donor bone marrow (BM) and peripheral blood (PB) HSCT that
require ≥10/12 high-resolution HLA A/B/C/DP/DQ/DR matches, unrelated donor CBT has
been performed safely with ≥4/6 HLA A/B/DR matches. One of the reasons for the reduced
HLA matching requirement of CBT is the decreased incidence and severity of acute and
chronic graft-versus-host disease (GvHD) following transplantation with cord blood (CB),
even with mismatched donors [2]. As such, unrelated donor CBT lends itself to minority
populations without large BM donor registries and disease indications prevalent in certain
populations without many adult donors, such as patients with thalassemia that are prevalent
in China, India, Southeast Asia and Middle East.
Though HSCT is currently the only cure for thalassemia, due to the scarcity of suitable related
and unrelated HLA-matched adult donors for most of the affected patient population, HSCT
for thalassemia has been underutilized. Due to its lowered requirement for HLA matching,
CBT has been touted as an ideal donor stem cell source for the cure of thalassemia for these
populations. Unfortunately, outcome from previous large series using CBT for thalassemia has
been underwhelming [3]. As a result, worldwide use of CBT for thalassemia has been even less
than that of adult donors. If patient survival can be improved when using CBT for thalassemia,
then utilization rate of this alternative donor source would greatly increase, as we have seen
from our experience in Taiwan where many of the pediatric thalassemia patients have been
cured in our collaboration with Chang Gung Children's Hospital [4–7]. To improve clinical
outcome for CBT for thalassemia in Taiwan, our focus has been to increase the stem cell,
progenitor cell and total nucleated cell doses transplanted into patients by (1) raising the
average cell dose of CB products in our inventory significantly through the use of Chow's
proprietary MaxCell CB processing technologies [8]; (2) using double CBT whenever feasible
and necessary [9]; (3) avoiding of the use of post-thaw wash either with direct thaw and
infusion or with thaw and reconstitution [8]; and lastly, (4) selecting the best combination of
optimally HLA-matched CB units that have high progenitor and total nucleated cell doses [6].
Currently, this strategy has been difficult to fully duplicate for other regions where thalassemia
is prevalent as large inventories using the proprietary MaxCell CB processing technologies
have been limited mostly to the Taiwanese patients for populations with high prevalence for
thalassemia.
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These strategies to improve patient survival and clinical outcome of CBT may have an impact
on other chronic nonlethal diseases, such as autoimmune diseases and HIV infections, that can
be cured with HSCT, which require high survival-to-mortality ratios to raise utilization rates.
Since 2001, Chow and his former colleagues at StemCyte have been working with City of Hope
to identify and establish a homozygous CCR5-Δ32 donor CB inventory. These efforts preceded
the first patient cured of HIV infection (the “Berlin patient”) in 2009 with HSCT using an adult
donor homozygous for the CCR5-Δ32 mutation. In 2001, Chow et al. patented the homozygous
CCR5-Δ32 donor HSCT technology that was acknowledged as the basis for the HIV infection
cure for the Berlin patient by Dr. Gero Hütter, the attending transplant physician for the patient
[10]. In the last few years, the StemCyte CB bank founded by Chow has collaborated with other
high-quality banks around the world to screen CB inventories from these banks to increase the
number of homozygous CCR5-Δ32 CB products available for transplantation of HIV patients.
Since the Berlin patient, we and others have been searching for suitable HIV patients to be
transplanted using this multi-bank homozygous CCR5-Δ32 donor CB inventory. For HIV
infection, the current bottlenecks are (1) the scarcity of HLA-matched CB donor products that
are also homozygous for the CCR5-Δ32 mutation that has sufficient cell dose for transplanta-
tion, and the (2) lack of HLA typing information on potential HIV patients who are candidates
for such transplantation. Nonetheless, HIV-infected patient requiring homozygous CCR5-Δ32
donors remains an ideal indication for unrelated donor CBT.
Lastly, the reduced incidence and severity of acute and chronic GvHD following unrelated
donor CBT may also factor into its potential preferential consideration as a hematopoietic cell
source for transplantation for autoimmune diseases (AD). This is because if GvHD and TRM
can be reduced, then allogeneic HSCT may be used more frequently. Currently, autologous
HSCT is most often used in the treatment of severe AD (SAD) due to the high early TRM and
severe GvHD associated with allogeneic HSCT; however, the remission rate is not ideal with
autologous HSCT.
2. Cure of thalassemia by hematopoietic stem cell transplantation
Thalassemia is a disorder characterized by the formation of abnormal hemoglobin and unequal
globin chain synthesis. It is one of the most prevalent genetic disorders in the world. There are
a global estimate of 270 million carriers of hemoglobin disorders, 80 million of them carrying
β-thalassemia. β-Thalassemia is common in the Southern Asia and Southeast Asian regions
(1–40%), especially China and India, Middle East (3%), Mediterranean (1–3%), and in malarial
tropical regions due to the selective heterozygote advantage against malaria, thus increasing
the frequency of β-thalassemia [11]. Current medical therapy consists of lifelong blood
transfusions to maintain hemoglobin levels between 9 and 10 g/dL to suppress the ineffective
anemia-causing erythropoiesis. Complications with hemosiderosis or iron overload as a result
of frequent transfusions have been curbed with the addition of iron chelation therapy, which
has doubled life expectancy [11]. Initial iron chelators were administered as a continuous
subcutaneous infusion for 8–12 h daily; however, limitations such as inconvenience, side
effects, prohibitive cost, pain and associated reduced compliance of parenteral administration
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led to the development of oral iron chelators, which have been demonstrated to be safer and
easier to be compliant, though still associated with certain side effects. Despite increasing life
expectancy and improving quality of life for children with thalassemia, transfusion and
chelation therapies have major pitfalls, stopping short of becoming a cure for thalassemia.
Endemic areas where thalassemia is most prevalent struggle with the cost of iron chelation
and the risks of hyper-transfusion causing blood-transmitted infections such as hepatitis B and
C. Developed countries often encounter patient compliance issues, as effective daily chelation
administration is often unpleasant and inconvenient. Even with modern transfusion and
chelation therapy, only 68% of patients with β-thalassemia are alive at the age of 35 [12].
Although there are considerable advancements in transfusion and iron chelation, HSCT
represents the only curative therapy for patients with β-thalassemia currently.
In 1982, the first successful marrow transplantation for thalassemia was performed on a child
by Donnall Thomas and his colleagues [13]. Subsequently, the first of several series of trans-
plants for thalassemia was reported by Lucarelli et al. [14–16]. Today, thousands of patients
with thalassemia have been treated using HLA-identical sibling donor bone marrow trans-
plantation (BMT). After decades of optimization by the Italian groups [14–16], over 1000
patients with thalassemia and sickle cell disease have been cured, mostly using HLA-identical
sibling donor BM. For low-risk Pesaro class 1 or 2 patients, related BMT could achieve
outstanding overall survival of 87–95% and thalassemia-free survival of 64–90%, depending
on the disease severity [11]. Even with class 3 (with extensive liver damage from iron overload)
patients, with certain new preparatory regimens, patients younger than 17 years can achieve
survival rates of 93% with only 8% autologous recovery rate [17].
Unfortunately, <30% of adults have HLA-matched siblings, especially in China, where the one-
child policy has hindered widespread use of related donor transplantation. Matched unrelated
adult donors also remain unavailable for most thalassemia patients, despite proving to be
acceptable alternatives for patients with thalassemia who lack a compatible family donor [18].
The lack of available matched unrelated adult donors is often due to the limited size or lack of
bone marrow registries for the endemic regions. Despite there being 14 million potential
unrelated adult donors registered in various international registries worldwide, current
inventories of HLA-matched donors are especially limited for patients of Asian descent, a
region where thalassemia is most prevalent, as the majority of the world's adult donor registries
are from Caucasian background. With the expansion of donor registries by tens of millions in
regions that are prevalent for thalassemia, the scarcity of donors may be alleviated; however,
the endeavor of building BM registries of tens of millions donors is quite cost prohibitive,
especially given that most of the countries in the endemic regions are developing economies.
Cord blood offers an alternative for the source of hematopoietic stem cells and is a faster and
more economical way to increase the supply of donor stem cells. In fact, unrelated donor CBT
may offer the best alternative to adult donor HSCT due to a more lenient requirement for HLA
matching, allowing patients to find suitable donors from banks that are several orders of
magnitude smaller than BM registries. The relaxed HLA matching requirement is a result of
less severe GvHD after CBT compared to adult donor HSCT, which resulted in improved
quality of life for patients due to the decreased requirement of GvHD prophylaxis. As such,
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related and unrelated CB may alleviate shortage of matched unrelated donors, since less
stringent HLA matching is acceptable. Moreover, due to the lower severity and incidence of
GvHD after CBT compared to BMT [19–22], CBT may be preferable to BMT for thalassemia
and other nonmalignant diseases, as the decreased GvHD incidence and severity greatly
improve quality of life for transplant patients. For thalassemia and other transplant patients
with nonmalignant diseases, GvHD offers no advantage of relapse reduction as in the setting
as for malignant diseases.
Unrelated CBT for treatment of thalassemia has improved significantly with judicious CB graft
selection and consideration of a number of factors, including transplant age, Pesaro class, CB
processing, cell dose and post-thaw processing. Working exclusively with CB produced by
Chow's proprietary MaxCell technologies, Jaing et al. achieved thalassemia-free survival close
to that of related CB transplantations [5, 6]; however, other studies using traditional red cell
reduced (RCR) CB (referred to as 1st Gen CB processing elsewhere in this book) produced poor
results and the authors advocated cautious use of CB only in clinical trials [3]. Transplant center
experience is an important factor in increasing CBT for thalassemia. Although unrelated CBT
has the potential for curing thalassemia, thereby drastically improving the quality of life for
the patient, it is still not considered optimal even with the industry's best practice due to CB
donor scarcity in thalassemia endemic areas, especially for MaxCell CB products, and lack of
optimal results for RCR CB. Even so, as blood transfusion and iron chelation therapies are
prohibitively expensive and not widely accessible in thalassemia endemic regions, unrelated
CBT becomes a viable alternative that is less costly in the long run. In addition, it should be
noted that unrelated CBT offers patients significant potential benefits—quality of life and
increased life expectancy—thus increasing the need for the optimization of CBT to better treat
patients.
Recently, a number of studies have shown significant success using related and unrelated
donor CBT. As expected, cell dose is the most critical factor for CBT success, as revealed by
almost every major study to date [19–22]. Theoretically cell dose may be less of a problem for
thalassemia since CBT is usually performed at an early age when patients have smaller body
mass and require less cell dose; however, due to the difficulties of eradicating the endogenous
erythron, cell dose has been found to be just as critical for both related and unrelated CBT for
thalassemia [6, 7, 23–26]. For unrelated CBT for thalassemia, Jaing et al. [6] established
institutional guidelines of 2.5 × 107/kg for single unit CBT and >3.7 × 107/kg combined nucleated
cell dose for double CBT, with at least one unit exceeding 2 × 107/kg. Moreover, at Chang Gung,
following the Minnesota recommendations of CD34+ cell dose of 1.7 × 105/kg minimum for
single unit CBT [27], with the combined CD34+ cell dose exceeding 3.0 × 105/kg for double CBT.
Due to the proven central importance of cell dose in CBT, different groups have employed
various strategies to optimize nucleated and CD34+ cell doses, such as the supplementation
of BM stem cells from the same donor to the CB graft [28–30], the use of double CBT when
single CB units do not have sufficient cell doses [5, 6, 26, 31–35], the avoidance of post-thaw
wash (when indicated), which invariably results in loss of cells [5, 6, 26, 32–50], and usage of
MaxCell CB as red cell reduction results in decreased cell recovery [4–7, 26, 31–55].
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Various other approaches have been tried to improve the outcome of CBT for thalassemia,
ranging from preference for superior HLA matches [4, 6, 26, 31, 34, 37, 51–53], usage of related
HLA-identical donors [23–25], directed sibling cord blood bank efforts [30, 56], consideration
of non-inherited maternal antigen (NIMA) matches [57], preference for IV busulfan over oral
formulations [6, 58], the addition of thiotepa to the conditioning regimen [24, 25], reduced
intensity conditioning regimens [3, 59, 60], the avoidance of methotrexate in the prophylaxis
regimen [23–25], third-party MSC co-infusion [59], and intrabone direct injection of cord blood
products [61, 62].
3. Related donor cord blood transplantation for thalassemia
In 1995, the first CBT for thalassemia was reported, using a HLA-identical sibling donor cord
blood for a two-and-half-year old [36]. Busulfan/cyclophosphamide conditioning regimen and
cyclosporine/methotrexate GvHD prophylaxis were used. The TNC dose was 3.9 × 107/kg, and
the thawed product was not washed and was directly infused on June 12, 1993. Neutrophil
and platelet engraftment were achieved by day +23 and day +27, respectively. The patient
experienced no GvHD, and the patient was alive and transfusion independent 48 months after
transplantation. The various studies using related donor CBT for thalassemia are summar-
ized in Table 1 [23–25, 28–30, 36, 56, 59, 63–68].
  [36] [64] [28] [65] [23] [29] SDCB [30, 56] [24] [25]
# Patients 1 2 3 CB
5 CB + BM
1 33 9; 2 + 
baby
donor's
PB
(1) 14 Thal
4/14 + PB
(2) 7 Thal
27 66
Age (yrs)
median
Range
2.5 2.2/3.8 4, 13, 15 3 5
1–20
5.5/
3.5–10
(1) NA
5.9/
2–11
6
0.8–18
5.9/
2–20
HLA A/B/DR
6/6 
5/6
≤4/6 matches
1 2 8 0
0
1
41
3
6
1
2
(1) 14 (2) 7 100%
0
0
100%
0/0
0/0
TNC dose
Median
Range
3.9 6.2/11.4 CB
2/1.2/2.5 
Combined
3.2/2.8/3.7
6.1 5.1/
1.2–13 PF
4.0/
1.2–10 PT
6.6/
3.4–12.7
(1) NA
(2) 4.7/
0.8–7.6
3.3
1.5–6
3.9
1.5–14
Engraftment
Myeloid
(ANC500)
Platelet 20/50K
ANC
1/1;
D+23
Plt
2/2 1/3CB
5/5 CB + BM
1/1 ANC
89%
D+23
(12–60)
5/9 (1) Thal 12/14
(2) Thal 6/6
with
engraftment 
100%
(27/27)
100%
(27/27)
ANC
90 ± 4%;
D +23
Plt
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  [36] [64] [28] [65] [23] [29] SDCB [30, 56] [24] [25]
(Plt 20K or
50K)
1/1;
D+37
D +39
(19–92)
data reporting 83 ± 5%;
D +38
Graft failure;
primary (PGF);
secondary
(SGF)
None None 2/3 CB None 7/33
(21%)
4/9;
2 PGF;
2 SGF
(1) 2 PGF + 1 SGF
(2) 1SGF
0 (0%) 10.4%
Acute GvHD 0 2/2 III
SR
None None 11%
(4/38) II
3/9 I/II SR
1/9 IV
(1) NA 0 (0%) 11% II–
IV
Chronic
GvHD
0 None None Limited 6% (2/36)
limited
1/9 (1) NA 0 (0%) 5 ± 3%;
0 ext
Survival OS 1/1
DFS 1/1
2/2
Alive &
TI
OS 8/8
DFS 7/8
0/1
Died
D +300
Thal
OS 100%
EFS 79%
OS 8/9;
1 death
aGvHD
IV 
4 TI
(1) Thal
OS 11/14;
DFS 11/14
OS 27
(100%)
DFS 27
(100%)
DFS
80 ± 5%
Follow-up (M)
median/range
48
(1995b)
11–24 (1) 18/
16–23
10 24/
4–76
49/
38–64
12.4/
0.5–77
40/
15–89
CB 70
(12–
151)
Thal = thalassemia major; CB = cord blood; CBT = cord blood transplant; MaxCell = non-red blood cell reduced cord
blood; RCR = red cell reduced cord blood; SCBT = single cord blood transplantation; DCBT = double cord blood
transplantation; NW = non-wash post-thaw processing; N/A = not available; LGF = late graft failure; AR = autologous
recovery; TI = transfusion independent; TNC = total nucleated cells in ×107/kg patient weight; CD34+ = total CD34+
Cells in ×105/kg patient weight; GvHD = graft-versus-host disease; aGvHD = acute graft-versus-host disease; Ltd = 
limited chronic GvHD; Ext = extensive chronic GvHD; TRM = transplant-related mortality; M = months; 3Y = 3 Year; 1Y 
= 1 Year; D = days post-transplant; OS = overall survival; DFS = disease-free survival; EFS = time interval from CBT to
first event (death or autologous reconstitution or infusion of cryopreserved backup recipient hematopoietic stem cells);
RR = relative risk; F/U = follow-up; CI = cumulative incidence; KM = Kaplan-Meier estimator survival. SR = Resolved
with Steroids; Thal = Thalassemia.
Table 1. CBT using related donors and sibling-directed donor CB bank (SDCB) for patients with thalassemia.
In 2013, Locatelli et al. published their landmark study for hemoglobinopathies on the
comparison of related HLA-identical HSCT with 66 thalassemia patients transplanted with
CBT against 259 thalassemia patients transplanted with BMT (Table 1) [25]. The CBT cohort
was younger (median age 6 versus 8 years; p = 0.02), had higher disease severity for the
thalassemia patients (Pesaro 2–3 39 versus 44%; p < 0.01), and was transplanted more recently
(median year 2001 versus 1999; p < 0.01), with a significantly higher percentage of BMT patients
receiving methotrexate GvHD prophylaxis than CB product recipients. No patients were
excluded except for patients who received a combination of CB and BM products. Most thawed
CB products were thawed and washed per Rubinstein procedure [20], and no information was
provided as to the type of CB processing employed for the units. Compared to BMT recipients,
the patients given CBT had slower neutrophil engraftment, less acute GvHD and no extensive
chronic GvHD. Graft failure occurred more commonly in CBT patients than recipients of BM
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grafts but not significantly (10.4 vs. 7.4%; p = 0.33). Eight of the patients who received CB graft
experienced graft failure. Cumulative incidence of primary graft failure was 9 ± 4% and 6 ± 4%
after CBT and BMT, respectively. Six patients experienced secondary graft failure after CBT at
a median of day +151 (range day +51 to 202). The cumulative incidence of neutrophil engraft-
ment was 90 ± 4% and 92 ± 1% (p = 0.01), and 83 ± 5% and 85 ± 5% for platelet engraftment after
CBT and BMT, respectively. For patients who engrafted, the median time to neutrophil
recovery was day +23 for CBT and day +19 for BMT, and day +38 and day +25 for CBT and
BMT for platelet engraftment, respectively (p = 0.004). The proportion of long-term sustained
mixed chimerism was significantly higher after CBT than for BMT (37 versus 22%; p = 0.01).
Only 11% of CBT recipients experienced grade II–IV acute GvHD (no grade IV), versus 21%
of BMT recipients (2% grade IV acute GvHD), with a cumulative incidence 10 ± 3% and 21 ± 
2%, respectively (p = 0.04). Only six of 84 evaluable CB recipients experienced chronic GvHD
with no extensive grade versus 42 of 355 (12 extensive) patients of BMT who survived past
100 days, with the cumulative incidence of chronic GvHD at 5 ± 3% and 12 ± 2%, respectively
(p = 0.12), and extensive chronic GvHD at 0% and 5 ± 9%, respectively. Twenty-one patients
expired from transplant-related causes—three after CBT and 18 after BMT. Most importantly,
with a median follow-up of 70 months, the 6-year DFS was 80 and 86% for CB- and BM-
transplanted patients, respectively, with no difference in multivariate analysis. This study
proved that CBT using related donor for thalassemia is as efficacious and safe as related donor
BMT, with potentially better long-term quality of life due to reduced chronic GvHD with
minimal extensive grades. The authors point out that the quality of life for BMT patients with
extensive chronic GvHD is worse than patients on medical therapy.
The author speculated that due to the higher nucleated cell dosage for most of the CB
recipients, nucleated cell dosage was not shown to influence engraftment or disease-free
survival. For CBT, methotrexate was shown in multivariate analysis negatively influencing
DFS (HR 3.81, CI 1.40–10.87; p = 0.004), with 6-year DFS at 90 ± 4% if methotrexate was
avoided versus 60 ± 11% (p < 0.001). Similar to previous studies, thiotepa-containing prepa-
rative regimen and Pesaro classification 1 were shown to correlate with better outcome
after CBT. These series using related CBT demonstrate the efficacy and high margin of
safety of related CB as a source of HSCT for thalassemia. The studies confirmed that even
with persistent mixed chimerism, patients are still transfusion independent. Methotrexate
GvHD prophylaxis was proven to be detrimental to favorable outcome and the addition of
thiotepa to busulfan and cyclophosphamide conditioning regimen favored sustained do-
nor engraftment.
4. Unrelated donor cord blood transplantation for thalassemia
Three single cases employing unrelated CBT for thalassemia were reported early on, with all
three patients achieving neutrophil engraftment and transfusion independence [65–67].
Busulfan/cyclophosphamide/ATG-containing preparative regimen was used in all three;
however, Fang et al. and Tan et al. used methotrexate-containing GvHD prophylaxis [65, 66].
Nucleated cell dose was high, with the minimum of 6 × 107 nucleated cells/kg. One patient
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received a 6/6 HLA A/B/DR-matched CB and two were transplanted with 4/6 HLA-matched
CB. None of the patients experienced chronic GvHD or Grade IV acute GvHD. Vanichsetakul
et al. [68] reported on six patients transplanted with three 6/6, one 5/6 and two 4/6 HLA-
matched CB from unrelated donors. Patients were ranged from 2 to 15 years old with a median
of 5.5 years. Busulfan, cyclophosphamide and fludarabine conditioning regimen was used
with cyclosporine and methylprednisolone GvHD prophylaxis. Median TNC dose was 2.8 ×
107 nucleated cells /kg with a range of 1.5–5.3 × 107 nucleated cells. Five of six patients engrafted
and survived, while one expired due to infection prior to engraftment. Soni et al. [60] reported
on unrelated CBT of two Pesaro class 3 patients with reduced intensity conditioning, with one
recipient requiring re-transplantation with CB. After re-transplant, both patients engrafted and
were thalassemia-free, with a follow-up of 7 and 8 years. Lastly, Kharbanda et al. [59] reported
on the use of unrelated CB supplemented with co-infusion of third-party mesenchymal stromal
cells (MSC) in two thalassemia patients, using a reduced intensity condition regimen. Only
one patient engrafted, with neither patient survived.
In 2004, Tang-Her Jaing at Chang Gung Medical Center and Robert Chow at StemCyte
embarked on a long-term collaborative study using unrelated CBT for thalassemia patients in
Taiwan with the hypothesis that if conditions were optimized, HLA-mismatched unrelated
CBT may produce results as favorable as unrelated BMT as well as approach that of related
BMT and CBT. One strategy was to transplant patients as early as possible when disease stage
is least severe. Most importantly, several approaches to optimize stem, progenitor and
nucleated cell doses were employed: (1) utilization of CB products that were not reduced in
RBC (MaxCell CB) whenever possible. Such non-RBC reduced, plasma depleted/reduced
MaxCell (“MaxCell” or “MC”) CB products have been shown to have significantly higher
recovery for nucleated cell, CD34+ cells and colony-forming units (CFU) following parallel
processing comparisons against RCR CB units [5, 8, 35, 39, 47, 48, 50]; (2) avoidance of post-
thaw washing unless contraindicated, which has been shown by us and several other groups
to be safe, offering enhanced infused cell dose due to zero cell loss from post-thaw washing [5,
6, 26, 32–34, 36–50, 69–71]; and (3) double CBT whenever cell dosage for single CB units was
insufficient to meet the study thresholds for nucleated and CD34+ cell doses [9, 31–35]. In
practice, the study complied with the first two conditions completely for all Chang Gung
patients who have been reported, by sourcing all of its CB products from a single manufacturer
of red cell-replete MaxCell CB products (StemCyte). Consequently, the average and median
cell dosages achieved in Chang Gung patients were higher than every other large unrelated
CBT series for thalassemia. The myeloablative conditioning and GvHD prophylaxis regimens
consisted of the standard busulfan, cyclophosphamide and ATG, as well as cyclosporine and
methylprednisolone, respectively. IV busulfan accompanied by drug level monitoring and
adjustment replaced oral busulfan after a cluster of several autologous recoveries. Initially, pre-
freeze nucleated and CD34+ cell dose criteria were set at 2 × 107/kg and 1.7 × 105/kg, respectively,
and were later raised to 2.5 × 107/kg (for single CBT) and 2.0 × 105/kg, respectively. Importantly,
the outcome data for Chang Gung transplant recipients were audited by CIBMTR appointed
auditors on site using actual patient charts as routine for StemCyte supplied CB, which has
been verified to be 97.3% accurate, with only minor errors and no errors for survival, mortality,
engraftment, GvHD or relapse.
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MC CBT
Jaing et al. [26]
MC CBT
Jaing et al. [6]
MC CBT
Petz et al. [5]
RCR CBT
Ruggeri et al. [3]
# Patients 45 total; 32 Thal 35 Thal patients;
5 Re-CBT 
120 total; 46 Thal 35 Thal
Type of CB 100% MC CB 100% MC CB 100% MC CB 100% RCR CB
Age (yrs) Median 4.5 5.5 3.5 4
Range 1.2–14 0.1–14
Pesaro class 1/2/3 21/9/0* N/A N/A 9/2/4
N/A 2 20
HLA A/B/DR 6/6 11 8 26 5
5/6 25 16 48 14
≤4/6 matches 27 28 53 16
TNC dose median 7.6 7.8 10.5 pre-freeze 6
Range 2.8–15.0 2.8–14.7 7.7 infused 2–32
CD34+ cell dose 4.0 4.0 3.7 N/A
Median/range 1.3–19.9 1.7–19.9
% CB not washed 100% 100% 58% NA
DCBT 13 DCBT 10 15 0
Approaches to
maximize cell dose
100% MC CB/
NW/±DCBT/CD34+
Priority
100% MC CB/
NW/±DCBT/CD34+
Priority
100% MC CB/
NW/±DCBT
NA
Engraftment CI
Myeloid ANC500 ANC500 88% ANC 88% ANC 87 ± 6% ANC500 42.8%
Platelet 20K (Plt20K) Plt 20K 82% Plt 20K 78% Plt 20K 81 ± 6%
Graft failure 4 Primary 5 Primary
1 Secondary
3 ± 2% 20/35
57.2%
Survival OS 5Y 88.1% OS 5Y 88.3 ± 6.7% OS 1Y 79 ± 4%;
3Y 79 ± 4% 
OS 62 ± 9%
DFS 5Y 77.1% DFS 5Y 85.7% DFS 1 Y 72 ± 5%;
3Y 70 ± 6%
DFS 21 ± 7%
2Y TRM 12% 2Y TRM 11.7 ± 6.7% TRM 100 D 10 ± 3%;
3Y 20 ± 4%
F/U (M) median/range  26/3–66 36/6–76 6.5 21/3–138
Acute GvHD II–IV 76% 6 I; 12 II 0–II 38 ± 5% 23 ± 2%
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MC CBT
Jaing et al. [26]
MC CBT
Jaing et al. [6]
MC CBT
Petz et al. [5]
RCR CBT
Ruggeri et al. [3]
III–IV 42% 15 III; 1 IV III–IV 19 ± 4%
Chronic GvHD 35%
1/14 extensive
13/35 limited
1/35 extensive
36 ± 6% Ltd.
12 ± 4% Ext.
8/35 Ltd.
2/35 Ext.
Severe infections 1 2/35 4/35
Thal = thalassemia major; Other = other nonmalignant indications; CB = cord blood; CBT = cord blood transplant; MC 
= non-red blood cell reduced cord blood MaxCell; RCR = red cell reduced cord blood; SCBT = single cord blood
transplantation; DCBT = double cord blood transplantation; NW = non-wash post-thaw processing; N/A = not
available; GvHD = graft-versus-host disease; Ltd. = limited chronic GvHD; Ext = extensive chronic GvHD; TNC = total
nucleated cells in ×107/kg patient weight; CD34+ = total CD34+ cells in ×105/kg patient weight; OS = overall survival;
DFS = disease-free survival; TRM = transplant-related mortality; M = months; Y = year; D = days post-transplant; F/U = 
follow-up; CI = cumulative incidence; KM = Kaplan-Meier estimator survival; * = Modified Pesaro (no liver biopsy),
which may underestimate the disease severity; @ = TC data audited by CIBMTR on site.
Table 2. Unrelated CB transplantation for patients with thalassemia—large series—3 MC CBT and 1 RCR CBT.
From 2005 onwards, the Jaing-Chow collaboration reported their experience of a number of
studies using unrelated CBT for thalassemia (Tables 2 and 3)—both Chang Gung Children
Hospital single institution experiences [4, 6, 26, 31–35, 37, 51–53, 58] and multi-institutional
studies from the StemCyte cord blood bank outcome database [5, 7, 35, 39, 42, 49, 54, 55]. The
first thalassemia patient transplanted by Jaing's group on October 2003 became the first
disease-free surviving CBT recipient in Taiwan [37].
A single institution series of unrelated CBT of 45 patients with nonmalignant diseases (32
thalassemia cases) was reported by Jaing's group in 2010 (Table 2). Most patients received
HLA-mismatched CB grafts with median infused nucleated and CD34+ cell doses at 7.6 × 107/
kg and 4.0 × 105/kg, respectively [26]. With cumulative incidence of neutrophil and platelet
engraftment at 88 and 82%, four patients experienced primary graft failure. Three patients
experienced grade IV acute GvHD and only a single patient suffered extensive chronic GvHD.
Five-year OS and DFS were 88.1 and 77.1%, respectively, and TRM was 12% at 2 years.
To study the effect of RBC-replete MaxCell CB in a series of 58 thalassemia patients performed
at nine U.S. and five non-U.S. transplant centers, Chow's group [33] compared 48 patients who
received MaxCell CB versus 10 patients who received RCR CB (Table 3). Though this initial
study was not rigorously matched, patients were similar among two groups in age, weight,
disease severity, TNC dose, #HLA matches, conditioning regimen, no post-thaw wash, and
transplant center experience. There were more double CBTs in the MaxCell group (23 versus
10%). The raw comparison results between the two groups showed no significant differences
in cumulative incidence in neutrophil (MaxCell 96 ± 4% vs. RCR 75 ± 15%; RR = 1.31; p = 0.56)
or platelet 50K engraftment (MaxCell 95 ± 5% vs. RCR 75 ± 15%; RR = 1.24; p = 0.64). Overall
patient survival at 1-year trended higher for MaxCell CBT (MaxCell 89 ± 6% vs. RCR 53 ± 20%;
RR = 0.32; p = 0.17); however, importantly, DFS was significantly higher at 89 ± 6% for MaxCell
CB compared to 38 ± 17% (RR = 0.17; p = 0.01).
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Jaing et al. 2008
matched pair (MP)
MC CB ARM
@ [32–34]
Jaing et al. 2008
matched pair (MP)
RCR CB ARM
@ [32–34]
Chow et al. 2012
MC CB ARM
@ [35]
Chow et al.
2012
RCR CB ARM
[35]
# Patients
Type of CB
58 Thal patients
48 MC patients
MP performed on 30 matched
pairs
30 MC patients vs. 10 RCR
patients
58 Thal patients
10 RCR patients
MP performed on 30
matched pairs
30 MC patients vs. 10
RCR patients
91 Thal.
79 MC CBT
91 Thal.
12 RCR CBT
Age (yrs) median Pre-match 5.0
post-MP 4.0
Pre-match 2.8
post-MP 2.8
MC 5.3 RCR 4.0
Range Pre-match 0.3–20
post-MP 0.3–12
Pre-match 1–12
post-MP 1–12
0.3–2 0.8–12
Pesaro Class 1 Pre-match 46% MP 57% Pre-match 50% MP 50% MC 27 RCR 6
Class 2 Pre Pre-match 20% MP 20% MC 17 RCR 2
Class 3 Pre Pre-match 10% MP 10% MC 0 RCR 2
N/A MC 35 RCR 2
Conditioning Multi-inst. Series Multi-inst. Series Multi-inst. Series Multi-inst.
series
Regimens Mostly BU/CY/ATG Mostly BU/CY/ATG Mostly
BU/CY/ATG
Mostly
BU/CY/ATG
GvHD
Prophylaxis 
CSA
MP
CSA
MP
Multi-
institution
series
Multi-
institution
series
HLA A/B/DR 6/6 Pre-match median 4.8 MP 4.5 Pre-match median 4.4
MP 4.4
MC 21 RCR 1
5/6 Pre-match range 3–6 MP 3–6 Pre-match range
4–6 MP 4–6
MC 38 RCR 3
≤4/6 matches MC 45 RCR 8
TNC dose median Pre-match 9.1 MP 9.1 Pre-match 8.9 MP 8.9 MC 9.8 RCR 8.7
Range Pre-match 2.5–47
MP 3.4–20
Pre-match 2.3–19
MP 2.3–19
2–23.7 2–18.6
CD34+ cell dose
median/range
N/A MC 3.6
0.4–10.3
RCR1.5
0.4–13.5
% CB not washed N/A MC 89%; RCR 77%
% DCBT Pre-match 11 (23%) MP 5 (17%) Pre-match 1 (10%) MP 1
(10%)
MC 20% RCR 8%
Engraftment
Myeloid ANC500
Platelet 20K/50K
(Plt20K or 50K)
Pre-Match ANC MC 96 ± 4% vs.
RCR 75 ± 15% (RR = 1.31; p = 0.56)
Pre-Match Plt50K MC 95 ± 5% vs.
RCR 75 ± 15% (RR = 1.24; p = 0.64)
ANC 83.2%
Plt20/50K
79/76%
MP ANC MC 88 ± 12% vs.
RCR80 ± 14% (RR = 1.05; p = 0.90; P = 
0.92)
MP Plt50K MC 88 ± 12% vs.
RCR 70 ± 17% (RR = 1.01; p = 0.98; P = 
0.73)
Graft failure MP 1Y MC 7 ± 5%;
RCR 22 ± 14%
(RR = 0.31; p = 0.24; P = 0.04)
N/A
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Jaing et al. 2008
matched pair (MP)
MC CB ARM
@ [32–34]
Jaing et al. 2008
matched pair (MP)
RCR CB ARM
@ [32–34]
Chow et al. 2012
MC CB ARM
@ [35]
Chow et al.
2012
RCR CB ARM
[35]
Survival Pre-matched pair
OS MC 89 ± 6% vs.
RCR 53 ± 20% (RR = 0.32; p = 0.17)
DFS MC 89 ± 6% vs.
RCR 38 ± 17%
(RR = 0.17; p = 0.01)
MC DFS
61.4%
RCR DFS
50.0%
Matched pair comparisons (MP)
3Y OS MC 96 ± 4% vs. RCR 53 ± 18%
(RR = 0.09; p = 0.03; P = 0.001)
3Y DFS MC 89 ± 6% vs. RCR 40 ± 15%
(RR = 0.17; p = 0.01;P = 0.0001)
3Y TRM MC 4 ± 4% vs. RCR 47 ± 18%
(RR = 0.09; p = 0.03;
P = 0.001) 
F/U (M) median/
range
9.5 6 23.7
Acute GvHD II–IV/
III–IV
N/A MC 75%/25% RCR 80%/20%
Chronic GvHD
Ltd/Ext
N/A MC 60%/5% RCR 100%/0%
Thal = thalassemia major; CB = cord blood; CBT = cord blood transplant; MC = non-red blood cell reduced cord blood
MaxCell; RCR = red cell reduced cord blood; SCBT = single cord blood transplantation; DCBT = double cord blood
transplantation; NW = non-wash post-thaw processing; N/A = not available; GvHD = graft-versus-host disease; Ltd = 
limited chronic GvHD; Ext = extensive chronic GvHD; TNC = total nucleated cells in ×107/kg patient weight; CD34+ = 
total CD34+ Cells in ×105/kg patient weight; CI = cumulative incidence; KM = Kaplan-Meier estimator survival; OS = 
overall survival; DFS = disease-free survival; TRM = transplant-related mortality; M = months; Y = year; D = days post-
transplant; RR = relative risk; p = p value of MC versus RCR matched pair comparison; P = paired Prentice-Wilcoxon
test p value; F/U = follow-up; * = modified Pesaro (no liver biopsy), which may underestimate the disease severity; @ = 
TC data audited by CIBMTR on site; MP = MC versus RCR CBT-matched pair analysis used a logistic regression model
to find patients with similar characteristics to form 30 pairs, with three MC patients matched to each RCR patient (30
MC patients to 10 RCR patients). Factors matched for were age, weight, #HLA matches, TNC dose, transplant center
experience. Univariate comparisons and paired Prentice-Wilcoxon test were performed for the matched pairs.
Table 3. Unrelated CB transplantation for thalassemia patients—comparison of MaxCell (MC) versus red cell-reduced
CBT.
To further minimize patient population differences and selection bias, Chow's group per-
formed a rigorous matched pair (MP) comparison analysis using a logistic regression model
to find thalassemia patients with similar characteristics to form 30 pairs (Table 3), with three
MaxCell patients matched to each of the available 10 RCR patients (30 MaxCell CBT patients
matched to 10 RCR CBT patients) [32–33]. Factors matched were age, weight, TNC Dose, #HLA
matches and transplant center experience. Since all available RCR patients were used in the
MP study, and the best-matched MaxCell patients were used in the matched pair, differences
in the matched factors were further minimized and selection biases were avoided. After
matched pairing, age, disease severity, # HLA matches, TNC dose and usage of double CBT
were quite similar between the two groups, with no significant differences. Univariate
comparisons and paired Prentice-Wilcoxon test (PPW) were performed for the matched pairs.
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The matched pair study results in Table 3 showed that though engraftment did not improve
significantly, autologous recovery rate was significantly lower in the MaxCell group at 7 ± 5%
versus 22 ± 14% (RR = 0.31; p = 0.04). Most importantly, 3-year OS (96 ± 4% versus 53 ± 18%;
RR = 0.09; p = 0.03 univariate and p = 0.001 PPW), 3-year DFS (89 ± 6% versus 40 ± 15%; RR = 
0.17; p = 0.01 univariate and p = 0.0001 PPW), and TRM (4 ± 4% versus 47 ± 18%; RR = 0.09; p = 
0.03 univariate and p = 0.001 PPW) were all significantly improved for the MaxCell CBT group.
It should be noted again that the RCR and MaxCell OS and DFS rates observed in this study
were similar to that reported for previously thalassemia series using unrelated CBT [3, 5–7, 26,
35]. Lastly, the outcome data for MaxCell CBT recipients were rigorously audited by CIBMTR
personnel on site at transplant centers using actual patient records and verified to be 97.3%
accurate, with no errors for major variables, such as engraftment, survival, mortality, autolo-
gous recovery, etc.
In 2012, Chow's group reported a multicenter series of 91 thalassemia patients transplanted
with unrelated CB between 1999 and 2011, 79 with MaxCell CB and 12 with RCR CB (Ta‐
ble 3), the largest series to date of unrelated CBT for thalassemia [35]. With 45% male recipients,
patient median age was 5.6 years (range 0.3–20) and median weight was 18.8 kg (range 4–80).
HLA matches were 23 cases at 6/6, 45 cases at 5/6, 54 cases at 4/6 and 3 cases at 3/6 HLA
A/B/DR matches. Median pre-freeze TNC dose was 9.4 × 107/kg and median pre-freeze CD34+
dose was at 3.2 × 105/kg—unusually high due to the exclusive usage of MaxCell CB products
and the patients’ young age in the study. Three-quarters of the patients were Asian and 84%
CB was infused directly without post-thaw wash/reconstitution. Seven patients received a
second CBT due to graft failure. Acute GvHD grade II–IV and III–IV occurred in 76 and 24%
of the patients, respectively, whereas 60% and only 5% of the patients exhibited limited and
extensive chronic GvHD, respectively. Overall, cumulative incidence of myeloid, platelet 20
and 50K engraftment of 83, 79 and 76% were achieved, respectively. Median times to myeloid
and platelet 20K engraftment were 17 and 47 days, respectively. Most importantly, 180-day OS,
1-year OS and 1-year DFS of 80, 74 and 61% were reported, respectively, with a median follow-
up of 711 days. Again, it is important to reemphasize that the outcome data for MaxCell CBT
recipients were audited by CIBMTR on site at transplant centers using actual patient records
and verified to be error-free for major clinical outcome measurements.
In their 2011 multi-institutional study, combined data of Eurocord, NYBC and CIBMTR,
Ruggeri et al. [3] reported on 35 thalassemia patients (Table 2). With median age of 4 years,
and mostly Pesaro class 1 and 2 patients (11 out of 15), this study used a variety of conditioning
regimens (30/35 myeloablative regimens) and mostly calcineurin inhibitor containing GvHD
prophylaxis (65% cyclosporine). Myeloid engraftment was only 42.8%, with 57.2% patients
suffering primary graft failure. Though 66% were alive, only 23% were alive and thalassemia-
free, with OS and DFS at 2-year post-transplant as estimated by Kaplan-Meier method as 62 
± 9% and 21 ± 7%, respectively (Table 2). Referring to the Jaing et al. series [26], the authors
concluded that “For UCB, only one group has reported 80% DFS at 2 years… DFS was not as
good as previously reported by Jaing and colleagues.” Besides the single-center versus multi-
institutional aspects of the two groups, the most obvious differences were the significantly
higher TNC dosage in the Jaing/Chow series [4, 6, 26, 31–33], caused by the exclusive utilization
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of RCR CB units in the Ruggeri et al. series [3] versus 100% MaxCell CB products used in the
Jaing/Chow series. In a similar multi-institutional setting, using exclusively MaxCell CB
products with 38% thalassemia patients, Petz et al. [5] reported 3-year OS at 79 ± 4% and DFS
at 70 ± 6% (Table 3). As discussed above, Chow et al. [35] showed that in 91 thalassemia
patients, employing MaxCell CB in 86.8% of the recipients, higher OS (73%) and DFS (61%)
were also achieved compared to patients from the Ruggeri et al. series who received RCR CB
units exclusively (Table 3).
In 2012, using exclusively unrelated MaxCell CB, Jaing's group transplanted 35 thalassemia
patients, with 12 patients receiving double CBT (Table 2) [6]. The authors explained that their
initial approach of using oral busulfan resulted in five primary and one secondary graft failures
due to high pharmacokinetic variability exhibited with oral busulfan, necessitating six re-
transplants. In this series, 88% of the transplants (35 first and 5 second transplants combined)
achieved neutrophil engraftment. Five-year OS was 88.3 ± 6.7% and 5-year DFS was 85.7% (30
of 35 patients) in this exclusive MaxCell CBT series. The 85.7% 5-year DFS of this experience
is in contrast to the 21 ± 7% 2-year DFS obtained by Ruggeri et al. [3] and compares very
favorably with the 80 ± 5% 6-year DFS for HLA-identical related CBT reported for Locatelli
series in 2013 [25].
5. Cure of nonmalignant diseases by cord blood transplantation
In Table 2, to assess whether this observation of the superior efficacy of MaxCell CB can be
extended to other nonmalignant diseases, Chow's group conducted a multicenter study of
transplantation of 120 patients who received MaxCell CB for nonmalignant diseases—46 for
thalassemia, 3 for sickle cell disease and 71 other nonmalignant indications [5]. To maximize
cell dose, besides using exclusively MaxCell CB, double CBT was used in 12% of the cases and
no-wash thaw procedure was used in 58% of the patients. Median TNC dose was 10.5 × 107/kg
at collection and 7.7 × 107/kg on infusion, and median CD34+ cell dose was 3.7 × 105/kg at
collection. Twenty-six, forty-eight and fifty-three patients were matched at zero, one and two
or more mismatches at HLA A/B/DR loci. Myeloid ANC500 and platelet 20K engraftment
occurred at a median of days +21 and +49, respectively. The cumulative incidences to myeloid
and platelet 20K engraftment were 87 ± 6% and 81 ± 6%, respectively. Autologous recovery
occurred in only 3 ± 2% of the patients in this population made up of 38% thalassemics.
Importantly, OS at 3-year was 79 ± 4%, whereas 3-year DFS was 70 ± 6%, respectively, with
100 days and 3-year TRM at 10 ± 3% and 20 ± 4%, respectively. Within the statistical power of
this series, univariate analysis showed that ABO match, recipient sex, age, myeloablative
conditioning regimen and CMV seropositivity were nonsignificant predictors of particular
outcome. Double CBT was associated with a significantly higher incidence of acute GvHD
grades II–IV (relative risk 2.23; p = 0.05). Higher pre-freeze CD34+ dose improved myeloid
(RR = 1.55; p = 0.05) and platelet (RR = 2.73; p = 0.05) engraftment, OS (RR of death = 0.30; p = 
0.05) and DFS (RR of death or relapse = 0.27; p = 0.02). In this study, TNC was not a significant
factor, unlike previous reports [3], probably because the usage of typical TNC dose thresholds
of 2.5 or 4.0 × 107/kg for analysis as in the Ruggeri et al. series was not applicable in this series,
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due to the low numbers of MaxCell CBT patients with such low TNC doses, making statistical
comparisons impossible. This anomaly is due to the significantly higher median and average
TNC doses afforded by the usage of MaxCell CB products.
By using these three simple strategies to improve infused cell dose—exclusive MaxCell CB
usage, not washing cord blood upon thawing (58%) and double CBT (12%) in this series at 46
U.S. and international centers, with divergent nonmalignant diseases, conditioning and GvHD
prophylaxis regimens—results consistently superior to other reported series using unrelated
RCR CB were obtained as shown in Table 2 [3, 68]. In fact, these results approached that of
Jaing et al. [6] in 35 thalassemia patients in a controlled environment at a single institution and
also transplanted exclusively with unrelated donor MaxCell CB that were 100% directly
infused upon thawing, proving that the adoption of this combination approach may be
efficacious in diverse nonmalignant settings, such as HIV infection and autoimmune diseases.
6. Cure of HIV infection by cord blood transplantation
The application of the highly active antiretroviral therapy (HAART) has significantly im-
proved the survival of HIV-infected patient and converted HIV infection into a chronic but
mostly nonlethal disease for those patients who can afford and tolerate HAART in developed
countries. Though significantly improving HIV treatment and patient survival, HAART alone
is not sufficient to remove the virus in the long term, with rebound expected without contin-
uous HAART treatment due to the long half-life of latent infected cells [72]. HAART cannot
cure patients of HIV infection as clinically undetectable plasma viremia may only be achieved
by life-long treatment with serious side effects and risks of viral rebound whenever treatment
is interrupted. The reservoir of latent HIV provirus persists in patients’ latent infected CD4+
T cells even with continued HAART and remains the major obstacle in achieving functional
cure for HIV despite the countless efforts to eliminate it. Compared with HIV-negative people,
HIV-infected patients are more prone to hematological malignancies including Hodgkin
disease (HD) and non-Hodgkin lymphoma (NHL) [73]. Hence, to optimize the life expectancy
and quality of life, and to reduce the economic burden of patients, actual cure of HIV is always
preferable. Abbreviated life expectancy, high costs, serious chronic side effects and patient
noncompliance of HAART therapy drives the search for a HIV cure. Due to existing techniques
in leukemia treatment, HSCT has been investigated as a favorable approach to eliminate the
HIV virus reservoir while also curing concomitant malignant diseases in the same patient.
The first clinical attempt to use allogeneic HSCT for cure of HIV infection was performed by
Hassett et al. [74]. The patient did not improve clinically, and the immunological status
remained stable or worsened. Retrospective analysis of reported cases by Hütter and Zaia [75]
showed negligible differences between HIV-positive and HIV-negative patients following
allogeneic HSCT. Such results are to be expected as HIV produced by the latently infected host
cells that survive the allogeneic HSCT re-infects the newly engrafted donor immune system.
HAART administration during and following allogeneic HSCT did not change the clinical
course, and HIV in all eight patients in these seven reports who discontinued HAART after
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HSCT rebounded in just a couple of days [76]. Of these, two patients from the Brigham &
Women's Hospital were reported initially to be negative for HIV using the most sensitive
techniques available following unrelated donor 10/12 HLA-matched HSCT. Unfortunately,
after HAART suspension, the virus rebounded in both patients within a few weeks. Without
the continued antiretroviral treatment, patients show viral rebound quickly and thus were not
functionally cured of HIV. In the study by Henrich et al., two patients received allogeneic HSCT
from wild-type chemokine receptor 5 (CCR5) donors and were both reported to be free of
detectable virus [77]. However, when HAART treatment was interrupted, viral RNA and
proviral DNA became positive again 12 and 32 weeks later [78]. Taken together, these attempts
appear to indicate that allogeneic HSCT alone is insufficient to eradicate HIV-1 infection.
As CCR5 is a required co-receptor with CD4 for entry of HIV-1 CCR5-tropic strains, and the
mutated form of CCR5 with a 32bp deletion (CCR5-Δ32 mutation) provides resistance to the
CCR5-tropic strains of HIV-1 in people homozygous for such mutation [79], Chow reasoned
that HSCT with CCR5-Δ32/Δ32 donor will confer such resistance to recipients after developing
complete donor chimerism, and if such recipients happen to be HIV-infected and contain only
or predominantly CCR5-tropic viruses, such patients may be cured of their HIV infection. In
2001, Chow et al. were the first to propose the use of CCR5-Δ32/Δ32 donor HSCT to cure HIV
infection and went on to file a patent application on the concept [80]. In vitro, CD4 cells from
people homozygous for CCR5-Δ32 are highly resistant to infection by CCR5-tropic HIV-1, the
dominant strains in vivo [81]. Even HIV-infected patients with heterozygous CCR5-Δ32
mutation genotype appear to derive partial benefits in the form of slower progression to
acquired immunodeficiency syndrome status [82, 83].
Chow's approach was subsequently validated by Hütter et al. several years later [84]. This HIV-
infected patient, now known commonly as the “Berlin patient,” became the first and only
known case in which a HIV-infected patient was functionally cured of HIV infection and
survived [85]. Dr. Hütter later acknowledged that the technology first disclosed by Chow et
al. in their 2001 U.S. patent application #09/998,832 [80] and subsequently in U.S. patent
application 2003/0099621 AI was the basis for the Berlin patient cure [10, 86–88], when he wrote
“…in 2001, R. Chow, founder of StemCyte, Inc., applied for a patent to screen allogeneic stem
cell donors for a beneficial gene with which to treat HIV infection (U.S. patent 2003/0099621
AI).” [88]. The Berlin patient was diagnosed with acute myeloid leukemia and HIV infection
and received an initial HSCT from an adult donor homozygous for the CCR5-Δ32 mutation.
The patient's leukemia subsequently relapsed, prompting a re-transplantation with graft from
the same donor. To this date, since the first transplantation, the patient has been free of HIV-1
infection by viral RNA load or proviral DNA in peripheral blood, gut, liver and brain tissue
samples, even though HAART was stopped during and after the first HSCT. The Berlin patient
achieved complete chimerism with homozygous CCR5-Δ32 genotype in his peripheral blood
monocytes after initial transplantation, and subsequently, after re-transplantation with the
same donor after leukemia relapse. With the absence of antiretroviral treatment for more than
8 years, viral RNA or proviral DNA has been undetectable in various tissues even with the
most sensitive techniques and has shown a complete clinical remission of HIV infection [76,
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86]. Although the case of the Berlin patient sheds light on one approach of curing HIV infection,
this result has not been easy to replicate on a large scale to date.
To expand on the success of the Berlin patient, Petz and Chow reasoned that the odds of finding
a 10/12 HLA A/B/C/DR/DP/DQ-matched adult donor who is also homozygous for the CCR5-
Δ32 genotype is several logs more difficult than the probability of a 4/12 HLA A/B/C/DR/DP/
DQ (matched for HLA A/B/DR loci only)-matched donor CB with the CCR5-Δ32/Δ32 geno-
type [87, 89, 90]. Starting in 2001, in collaboration with John Zaia, Joseph Rosenthal, John Rossi
and Stephen Forman of City of Hope, Chow and Petz started screening StemCyte's CB
inventory for the homozygous CCR5-Δ32/Δ32 and heterozygous CCR5-Δ32 genotypes. As
Hütter et al. commented in 2011 “…Chows’ group built a database with over 10,000 cord blood
units, genotyped for the CCR5-delta32 deletion [10].” By 2007, Chow, Petz and City of Hope
investigators started to plan for a clinical trial with Yvonne Bryson, Ron Mitsuyasu, Mary
Territo, Ted Moore and Tempe Chen from UCLA [90]. By 2009/2010, the CB inventory screening
process was expanded to include additional CB banks, and probability of finding matched CB
units at various HLA match level and cell doses was calculated with the assistance of the
National Marrow Donor Program [87]. By 2013, 180 CCR5-Δ32/Δ32 CB units have been
identified [89].
To demonstrate the feasibility of CCR5-Δ32/Δ32 CBT to prevent HIV infection in an in vitro
model, Petz et al. reported a case when a HIV-negative adult with acute myelogenous leukemia
received CCR5-Δ32/Δ32 CBT [87], who engrafted showing complete donor chimerism. In vitro
HIV infectivity tests were performed using the patient's engrafted CCR5-Δ32/Δ32 peripheral
blood mononuclear cells (PBMCs) challenged with both CCR5-tropic and CXCR4-tropic HIV
laboratory strains (BAL and NL4-3). Both viral strains showed no replication activities when
cultured with the patient's engrafted CCR5-Δ32/Δ32 PBMCs, but exhibited robust replication
with PBMC from control wild-type (WT) CCR5 or heterozygote CCR5/CCR5-Δ32 individuals,
thus demonstrating resistance to HIV-1 of CBT derived donor PBMCs. These in vitro results
further support the feasibility of curing HIV by CCR5-Δ32/Δ32 CBT.
Table 4 highlights the eight cases of using homozygous CCR5-Δ32/Δ32 donor HSCT per-
formed up to 2014, with five using adult donors and three using CB plus or minus a second
graft. Except for the two patients performed in Berlin (the Berlin patient and one patient with
yet unpublished outcome), all have expired [91]. In the three adult donor cases performed
outside of Berlin, one died from infection after 4 months and one from pneumonia shortly post-
transplantation. In the last case, CXCR4-tropic virus rebounded after transplantation [92] and
the patient expired from Non-Hodgkin's Lymphoma relapse after 12 months. Prior to trans-
plantation, the patient appeared to have mixtures of CCR5-tropic and CXCR4-tropic viruses,
though HAART therapy prior to transplantation caused a shift to predominantly CCR5-tropic
viruses. CXCR4-tropic viruses emerged as the dominant viral type after HSCT probably as a
result of the selection in the absence of functional CCR5 receptor. Though rebound occurred
with HIV with alternative tropism, this case confirms the effectiveness of the CCR5-Δ32/Δ32
blockade of CCR5-tropic virus cell entry. Moreover, the emergence of viruses using alternative
co-receptors does not negate the possibility of a sterilization cure using this approach of
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patients infected predominantly with CCR5-tropic HIV, since it was the only case out of seven
with known outcome where viral tropism switch occurred.
Transplant center Adult donor graft
cases 
Patient
age
Concomitant
indication
Clinical outcome after transplantation
Berlin, Germany
2009
HLA-matched
unrelated
40 AML Alive after 8 years; no viral rebound without
ART [10, 75–76, 84–91]
Munster,
Germany
HLA-mismatched
unrelated
51 NHL Died from infection after 4 months [91]
Essen, Germany HLA-matched
unrelated
27 NHL HAART discontinued after HSCT. CXCR4-
tropic HIV–1 rebound, died from NHL relapse
after 12 months [91–94]
Santiago, Chile HLA-matched
related
46 NHL Died from pneumonia shortly post-transplant
[91]
Berlin, Germany
2015
NA NA NA NA [76, 91]
CB donor graft cases
Utrecht, the
Netherlands
CB + Haploidentical
graft
53 MDS HAART continued after HSCT. Died from
MDS relapse and pneumonia after 2 months
[91, 93, 94]
Minneapolis,
USA
CB Alone 12 ALL No viral rebound. Died from leukemia/GvHD
after 3 months [76, 91]
Barcelona, Spain CB + haploidentical
graft
37 NHL Died from relapse of non-Hodgin's lymphoma
after 3 months. No viral rebound prior to death
[91, 95–96]
CB = cord blood; AML = acute myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's
lymphoma; ALL = acute lymphoblastic leukemia; ART = anti-retroviral therapy; GvHD = graft-versus-host disease.
Note: One more CCR5-Δ32/Δ32 Donor HSCT was performed on a non-HIV-infected patient [87].
Table 4. CCR5-Δ32/Δ32 donor HSCT performed on HIV-infected patients up to 2014 [10, 75–76, 84–96].
In the three cases where CBT was employed with a CCR5-Δ32/Δ32 CB graft, one was a single
CBT, with this Minneapolis patient expiring from GvHD after 3 months [91]. In the other two
cases (the Barcelona and Dutch patients), both patients died from disease relapse prior to the
fourth month, with the Dutch patient also suffering from pneumonia [91, 93, 94].
The Barcelona case was a 37-year-old HIV-1-infected patient with aggressive lymphoma who
failed after five rounds of radiochemotherapy and an autologous HSCT. In the absence of a
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matched sibling donor, the patient received an allogeneic 4/6 HLA A/B/DR-matched unrelated
donor CCR5-Δ32/Δ32 CB product from the StemCyte inventory, supplemented with purified
CD34+ cells from a haploidentical sibling [95, 96]. By genotypic and phenotypic analysis, the
Barcelona patient's HIV strain was CCR5-tropic, with 2.1 copies of replication competent HIV
per 107 CD4 T cells and 303 copies per ml enumerated by single copy assay. After HSCT with
CCR5-Δ32/Δ32 CB and haploidentical sibling donor purified CD34+ cells, plasma HIV DNA
load was confirmed to be undetectable using ultrasensitive analysis. Upon reaching full
chimerism with the CB donor, the patient's engrafted CCR5-Δ32/Δ32 CD4 T cells responded
to proliferation and activation stimuli in vitro but was resistant to infection by the patient's
viral isolate and laboratory strains. Unfortunately, death related to lymphoma progression
prevented long-term monitoring of the patient's status; however, this case shows the potential
promise and utility of CCR5-Δ32/Δ32 CBT in curing HIV if the patient was infected with CCR5-
tropic virus [96].
Despite incredible worldwide attention and many attempts to replicate the success of the Berlin
patient, why has there been no other successful cured long-term survivors reported to date?
For one, HSCT is a highly risky procedure, with expected worse survival in advanced cases of
malignancies. Malignancy is a feature which all of these seven cases share [91]. Four of the six
cases expired because of or partially due to relapses from their malignant conditions. The other
cases died from infection or pneumonia—all common causes of post-transplant mortalities.
Only one case out of eight reported viral rebound, albeit with virus of a different tropism which
already existed in the patient prior to transplantation, perhaps indicating that viral rebound
through tropism switch is not as easy as one might hypothesize [92].
Currently, the most important barrier to having a large CCR5-Δ32/Δ32 adult donor or CB
inventory is the expense and logistical difficulties of screening millions of adult donors or
hundreds of thousands of CB archival samples. The 26,000 StemCyte CB units, 10,000 CB units
from the M.D. Anderson bank and 8000 adult donors tested in the German Red Cross Donor
Registry represent the largest repositories screened for CCR5-Δ32/Δ32 genotypes to date. As
such, the current availability of HLA-matched CCR5-Δ32/Δ32 homozygous donors is still
extremely limited. The frequency of homozygous CCR5-Δ32 is around 1% in Caucasians, even
less in the Middle East and 0% or almost 0 in Africa and in Asian countries like Taiwan, China
and Japan [75, 87]. The requirement for rigorous co-selection of both suitable HLA matches
and CCR5-Δ32/Δ32 genotypes leads to difficulties in finding appropriate adult donors to treat
HIV infection with hematopoietic stem cells from adult donors. Cord blood, however, can
tolerate 1 or 2 HLA A/B/DR mismatches and does not necessarily need HLA matches for HLA
C/DP/DQ loci; therefore, a CCR5-Δ32/Δ32 CB inventory gives rise to a higher probability of
finding a suitable CCR5-Δ32/Δ32 CB unit for individual patients [87, 97]. Instead of needing
to find a 10/12 HLA A/B/C/DR/DP/DQ match for homozygous CCR5-Δ32/Δ32 adult donors,
the chances of a 4/12 A/B/C/DR/DP/DQ homozygous CCR5-Δ32/Δ32 CB donor unit are several
logs easier, despite the cell dose limitations of CB products and the smaller sizes of CB
inventories compared to bone marrow registries worldwide. In fact, the difficulties in the
logistics and incredible cost barriers of screening tens of millions of adult donors for the CCR5-
Δ32/Δ32 genotype cannot be over-emphasized. In contrast, with readily available archived
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samples and smaller inventories to screen, screening CB banks’ products is an easier and less
expensive proposition. Moreover, the fact that CB banks are cryopreserved physical invento-
ries instead of a virtual database allows for easier construction of large banks of genotyped
and infectious and genetic disease-screened samples, perpetually available for immediate
shipping and transplantation with no possibility of donor refusal.
To explore the potential of CB stem cells as a more accessible source for curing HIV through
HSCT, starting in 2001, working with City of Hope, Chow and Petz started screening for CCR5-
Δ32/Δ32 genotypes of ∼18,000 Caucasian and ∼8000 Asian CB units and identified 134
Caucasian and 0 Asian CB units with the CCR5-Δ32/Δ32 genotype from StemCyte Interna-
tional Cord Blood Center [87]. During the last few years, additional CB inventories from other
cooperating CB banks are being tested, and the CCR5-Δ32/Δ32 unit number has grown to ∼180
by 2013 [89] with the hope of increasing the inventory to at least 300 CCR5-Δ32/Δ32 CB units
[87]. Studies have shown that the engraftment and survival of CBT recipient are highly
dependent on the number of nucleated and CD34+ cells. The most commonly accepted
threshold for TNC dose is 2.5 × 107 nucleated cells/kg recipient body weight, but this number
may not be achieved by all CB units collected, especially for adult patients. Delayed engraft-
ment and immune reconstitution are observed with CBT due to the low progenitor cell
numbers in CB products. With a theoretical inventory of over 300 CCR5-Δ32/Δ32 cryopre-
served units, working with the NMDP bioinformatics team, it has been predicted that the ≥4/6
HLA match rate would be 73.6% for Caucasian pediatric patients (younger than age of 16) at
the minimal TNC dose of 2.5 × 107 nucleated cells/kg recipient body weight. Far lower rates at
≥ 4/6 HLA match are found for adult patients (16 years or older) of all race groups at this
minimal TNC dose of 2.5×107 nucleated cells/kg recipient body weight – 27.9% for Caucasian,
2.7% for Chinese-American, 9.9% for African-American, and 14% for Mexican American. To
overcome the problems of insufficient cell dose with CBT, double and sequential CBT methods
have been developed to overcome this restraint, expand the access of CBT to patients and
improve transplantation outcomes [98–100]. With the option of double CBT, the minimum
number of nucleated cells necessary for successful transplant drops to a minimal TNC of 1.0 
× 107 nucleated cells/kg for each CB unit and 2.5 × 107 nucleated cells/kg for the combined cell
dose, thus allowing more patients, especially adult and heavier pediatric patients, to have the
access to suitable CB donors [100]. According to Petz et al., the rate of finding 4/6 HLA-matched
units can reach 85.6% for Caucasian pediatric patients and 82.1% for Caucasian adults, when
only 1.0 × 107 nucleated cells/kg is applied as the selection criteria [87].
Unfortunately, the possibility of finding two 4/6 HLA-matched CB products for double CBT
for a single HIV-infected patient out of a small 300 CCR5-Δ32/Δ32 CB unit inventory is also
remote. Since that probability approximates zero, to reach a combined TNC of 2.5 × 107
nucleated cells/kg is essentially the same as just using a single CB unit with TNC of 2.5 × 107
nucleated cells/kg. As you can see from Table 5, as such, the chances of a double CBT with
both CB units being homozygous for the CCR5-Δ32 mutation and with combined TNC ≥2.5 
× 107 are expected to be similar to the probability of finding a single homozygous CCR5-Δ32/
Δ32 CB unit with TNC ≥2.5 × 107 projected by Petz et al. [87].
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Double CCR5‐Δ32/Δ32 CBT CCR5‐Δ32/Δ32 CBT + WT CCR5 OR CCR5/
CCR5‐Δ32 CBT OR Haploidentical Adult
Donor Transplant
Adult patients @
combined CCR5‐
Δ32/Δ32 CB TNC
≥2.5 × 107
Pediatric patients @
combined CCR5‐
Δ32/Δ32 CB TNC
≥2.5 × 107
Adult patients @
CCR5‐Δ32/Δ32 CB
TNC ≥1.0 × 107
Pediatric patients @
CCR5‐Δ32/Δ32 CB
TNC ≥1.0 × 107
Caucasians
6/6 HLA A/B/DR matches  ∼0.01% ∼0.01% 0.09% 1.01%
≥5/6 HLA A/B/DR matches ∼4.5% ∼10.6% 10.7% 10.8%
≥4/6 HLA A/B/DR matches ∼27.9% ∼73.6% 82.1% 85.6%
Chinese American 
≥4/6 HLA A/B/DR matches ∼2.7% ∼12.3% 13.9% 15.7%
African American 
≥4/6 HLA A/B/DR matches ∼9.9% ∼28.6% 31.6% 34.1%
Mexican American 
≥4/6 HLA A/B/DR matches ∼14% ∼44.1% 48.9% 52.5%
Adapted from Petz et al. [87].
Table 5. Projected match rate with an inventory of 300 CCR5-Δ32/Δ32 cord blood units using double CCR5-Δ32/Δ32
cord blood transplantation strategy versus the CCR5-Δ32/Δ32 Cord blood + bridging CCR5 or CCR5/CCR5-Δ32 cord
blood or haploidentical donor strategy.
Instead of homozygous CCR5-Δ32/Δ32 double CBT, we and others have proposed alternative
“bridging” strategies. If a single CCR5-Δ32/Δ32 CB unit does not meet the ideal 2.5 × 107
nucleated cells/kg recipient body weight cell dose threshold, a second CB unit with either wild-
type (WT) CCR5 or heterozygous CCR5/CCR5-Δ32 donor may be used in a double CB
transplant (“the CCR5-Δ32/Δ32 CB + CCR5 CB OR CCR5-Δ32/Δ32 CB + CCR5/CCR5-Δ32 CB
double CBT strategy”). Alternatively, it is possible to combine the first homozygous CCR5-
Δ32/Δ32 CB product with a bridging haploidentical adult donor with wild-type CCR5 or
heterozygote CCR5/CCR5-Δ32 genotype as a second graft to “bridge” the patient until the
homozygous CCR5-Δ32/Δ32 CB unit has engrafted (“the CCR5-Δ32/Δ32 CB + haploidentical
CCR5 donor OR CCR5-Δ32/Δ32 CB + CCR5/CCR5-Δ32 haploidentical adult donor strategy”)
[76, 91, 94, 101]. This was the strategy tried for the Barcelona and Dutch patients [93, 94, 96].
The hope is that the survival advantage of CCR5-Δ32/Δ32 CB against HIV infection and lysis
of wild-type CCR5 or heterozygote cells would enable the homozygous CCR5-Δ32/Δ32 donor
CB to prevail over the wild-type CCR5 or heterozygous CCR5/CCR5-Δ32 CB or haploidentical
adult graft eventually. Since wild-type CCR5 or heterozygote CCR5 donors are readily
available, this strategy will yield far higher probability of finding a match since only TNC ≥1.0 
× 107 /kg is required for the first homozygous CCR5-Δ32/Δ32 CB product. As seen in Table 5,
the effect of just requiring TNC ≥1.0 × 107/kg for the first homozygous CCR5-Δ32/Δ32 cord
blood product resulted in a much higher match rate for adult patients—27.9 to 82.1% for
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Caucasians, 2.7 to 13.9% for Chinese Americans, 9.9 to 31.6% for African Americans and 14 to
48.9% for Mexican Americans. Moreover, if this strategy is combined with Chow's MaxCell
CB processing technologies and no-wash direct infusion strategy, then the probability of
finding a CCR5-Δ32/Δ32 CB product with higher cell dose further increases [1, 8].
Instead of having HIV-infected patients search for matched donor CCR5-Δ32/Δ32 CB, the more
efficient strategy may be for the limited CCR5-Δ32/Δ32 donor inventory to find matched HIV
patients who have concomitant transplant indications [1]. In this scenario, instead of having
HIV-infected patients searching for CCR5-Δ32/Δ32 donors, it is possible to reverse the process
and have the HLA type CCR5-Δ32/Δ32 CB or adult donors database, look for HIV-infected
individuals with transplant indications who have suitable HLA matches among the CCR5-
Δ32/Δ32 inventory. The math of a patient looking for a graft and a graft looking for a patient
is the same, just in the opposite directions; however, this allows targeted CCR5 genotype
screening of HIV patients who are in need of a HSCT [1].
Overall, HSCT has the potential to accomplish functional or sterilization cure of HIV patients
and would be especially valuable to HIV patients with hematological malignancy, which may
cure both indications with the same HSCT. Cord blood could be a more accessible alternative
to HLA-matched adult donor for curing HIV infection through HSCT, even though more
clinical trials on HIV patients would be necessary to establish the efficacy in eradicating HIV
infection for both adult donor HSCT and CBT. Due to the difficulties of co-selecting for units
with ≥4/6 HLA A/B/DR matches, suitable nucleated or CD34+ cell doses and the CCR5-Δ32/
Δ32 genotype, innovative strategies such as (1) double grafts combining a homozygous CCR5-
Δ32/Δ32 CB with either another wild-type or CCR5/CCR5-Δ32 heterozygote graft, (2) com-
bined with MaxCell CB processing and thawing technologies that yield higher cell doses and
(3) the employment of the reverse strategy of looking for matched HIV patients in need of
HSCT, can be helpful in expanding the utility of the CCR5/CCR5-Δ32 CB inventory for viable
transplantation. Actively screening for more CCR5-Δ32 homozygous CB units, establishment
of more comprehensive HIV-infected patient HLA type database and the application of double
CBT or bridging strategies would eventually allow more HIV-infected patients find suitable
units for transplantation.
7. Cure of autoimmune diseases by cord blood transplantation
Although many patients with autoimmune diseases (AD) can have a relatively normal life
expectancy with treatment, some patients with severe, progressive and therapy-refractory
autoimmunity require more than medication. Patients with systemic sclerosis (SSc), for
example, have shown disappointing results in prospective randomized trials of almost all
therapeutic agents reported [102]; therefore, HSCT, both autologous and allogeneic, has been
proposed as an effective potential treatment for such patients.
The basis for autologous HSCT for AD is the immune system reset by the generation of fresh
self-tolerant lymphocytes after chemotherapy-induced elimination of self or auto-reactive
lymphocytes. Elimination of auto-reactive T-effector cells, long-living plasma cells and
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antigen-presenting cells as well as increased T-regulatory cells, restoration of thymic function,
normalization of T-receptor repertoire, reduced auto-antibodies and long-lasting lymphopenia
are the intended effects of autologous HSCT for AD [103]. Autologous HSCT carries the risk
that if the basic defect of the AD is in the stem cell, the autoimmunity will probably recur after
autologous HSCT; however, if the primary defect is an aberrant immune response to an
acquired, for example, viral antigen, or self-antigen, there is a theoretical possibility that
tolerance may be acquired in the newly reconstituted autologous immune system—assuming
ablation of the offending memory cells.
Autologous HSCT has been applied to treat severe autoimmune diseases (SAD) since 1996
[104], when some of the first autologous transplants specifically for AD were performed by
Tyndall and colleagues [105]. Autologous HSCT for AD is based on the elimination of auto-
reactive effectors through potent immunosuppressive conditioning followed by subsequent
regeneration of self-tolerated lymphocytes capable of “resetting” the immune system. This
approach has been recognized to induce remission for some patients with various AD,
including SSc, systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid
arthritis (RA), adjuvant arthritis and severe Crohn's disease [104–112]. Multiple sclerosis has
been the main indication for autologous HSCT, along with SLE, therapy-refractory Crohn's,
vasculitis, autoimmune cytopenia, diabetes mellitus type 1, polyarthritis, adults with rheu-
matoid arthritis and children with juvenile idiopathic arthritis; however, RA relapse is
frequent [103]. According to the data from European Group for Blood and Marrow Trans-
plantation (EBMT) registry from 1996 to 2007, the 5-year OS was 85% among the 900 patients
who underwent autologous HSCT for AD; however, the 5-year progression-free survival (PFS)
was only 43% [104]. Even lower values, 33% for 5-year PFS (78% for 5-year OS), were reported
by the British Society of Blood and Marrow Transplantation (BSBMT) data registry for 1997–
2009 [113]. Although these studies proved the relative safety of autologous HSCT, the fact that
more than half of the patients suffered from disease relapse is unsatisfactory. This was
especially problematic for patients with RA, with a 3-year PFS of only 23% despite its high 3-
year OS of 98% [104]. This tendency to relapse was also confirmed in the report from Snowden
et al. [111]. With data from both EBMT and Autologous Blood and Marrow Transplant Registry
(ABMTR), Snowden suggested that the majority of RA patients experienced a reactivation of
the disease eventually and required the re-introduction of immunosuppressive drugs. Though
somewhat better than RA, autologous HSCT for other ADs is also hampered by disease
progression or relapse, showing unimpressive 3-year PFS ranging from 34 to 63% [104]. Illei
and colleagues suggested that the reactivation of lupus is a major contributing factor to the
deaths of SLE patients after autologous HSCT treatment [114]. Similar association between
autologous HSCT and relapse was also identified with SSc patients [115]. T cell depletion has
been proposed to be a relapse-preventing strategy in several clinical trials; however, no
significant improvement in either OS or PFS has been observed [104]. The unavoidable high
recurrence rate, together with the elevated risks of stem collection procedures on AD patients
themselves, lead to increased adverse events or even mortality of patients.
Compared to autologous HSCT, which only produces sustained responses in 30–40% patients,
allogeneic HSCT can achieve sustained response in 60–70% patients [113]. Allogeneic HSCT,
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which does not need stem cell collection from the patient and is less prone to disease relapse,
is therefore considered higher GvHD and TRM risk, but may produce more favorable long-
term results with AD relapse. In fact, evidence for the potential of HSCT to cure or ameliorate
AD comes from many cases when patients undergo allogeneic HSCT for another indication
with coincident AD, such as RA, psoriasis, psoriatic arthritis and ulcerative colitis, with the
AD often in remission post-transplant. Moreover, the converse observation has also been
reported, that is, passive transfer of AD from the donor graft through allogeneic HSCT,
including myasthenia gravis, Graves’ disease and autoimmune diabetes mellitus.
In all but one of the cases reporting the use of allogeneic HSCT for concomitant AD, the donor
was an HLA-identical sibling. Therefore, one possible explanation for recurrence of the AD
may be the presence of shared genetic factors between the related donors and recipients.
Another possible explanation is the persistence of host immune cells resulting in recurrence
of disease activity. These case reports, although small in number, were important in establish-
ing our understanding of the potential role of allogeneic HSCT for treatment of patients with
severe autoimmune diseases.
The failure of autologous HSCT to cure spontaneous-onset AD and to maintain long-term
regression could be due to the incomplete elimination of self-responsive memory T cells and
B cells. While the conditioning regimes through chemotherapy or irradiation are unable to
eradicate every single memory lymphocyte, complete immune ablation can be achieved by
allogeneic HSCT via combined effects of immune system replacement and graft-versus-
autoimmunity (GVA) effect [116]. In allogeneic HSCT, the host auto-reactive immune system
is replaced by the donors’ non-auto-reactive, but potentially alloreactive cells. Therefore,
alloreactive donor lymphocytes can undergo a GVA process similar to the graft-versus-
leukemia (GVL) effect or GvHD and attack the residual self-reactive host effectors [116, 117].
Thus, the biggest problem with allogeneic adult donor HSCT for AD is GvHD. In fact, several
cases of complete donor chimerism after adult donor HSCT cured the patients’ AD, but were
accompanied by severe acute or chronic GvHD post-transplant [118, 119]. In contrast, cases of
mixed chimerism, which sometimes occurs with reduced intensity or non-myeloablative
conditioning regimens, often exhibit mild and sometimes no GvHD [120–122]. Despite the
differences in the conditioning regimen used by the different groups, many patients treated
with allogeneic HSCT have shown sustained remission to AD and amelioration of symptoms,
and among patients with severe treatment-refractory ADs, the response rate was higher than
75% [123]. With reduced intensity conditioning, the adverse effects and treatment toxicity
observed in myeloablative autologous HSCT could be reduced [107]. However, relatively high
transplant-related mortality (22.1% at 2 years and 33.7% at 5 years) and GvHD remain as the
biggest challenges to allogeneic HSCT for AD [123]; yet, the 5-year OS for allogeneic HSCT is
not significantly different than the 78% 5-year OS for autologous HSCT reported by the
BSBMT [113], but appears to be lower than the 85% OS for autologous HSCT reported by the
EMBT [104].
To minimize the risks of GvHD with allogeneic HSCT for AD, there are emerging interests in
using CB as the alternative source of stem cells to the traditionally used (or simply “tradition-
al”) adult stem cell sources of bone marrow (BM) and peripheral blood (PB). While tolerating
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far greater degrees of HLA mismatch, CBT is still associated with lower incidences and severity
of acute and chronic GvHD than HSCT from adult donors [124]. According to the recent study
of 143 patients in 2010, the rate of grade II or higher GvHD is only 9% among HLA-matched
(n = 60) and 50% among HLA-mismatched (n = 18) patients [125]. Being less mature than stem
cells from adult grafts, CB stem cells show lower alloreactivity and immunogenicity without
increasing long-term relapse incidences [126]. Moreover, CB has other advantages including
low contamination rate, easy storage and immediate accessibility via cryopreservation [125].
Together with its relatively lenient requirement for HLA matching, CB has been used com-
monly as an alternative source for transplantation. Indeed, one of the first cases to treat AD
with CBT was performed due to lack of HLA-matched, appropriate adult stem cell source
[127]. Raetz and colleagues performed myeloablative conditioning HSCT on a 5-year-old boy
with severe Evans syndrome, which consists of immune thrombocytopenia and Coombs-
positive hemolytic anemia. The graft was a CB from an HLA-matched sibling with 3.85 × 107
nucleated cells/kg patient and 0.96 × 105 CD34+ cells/kg patient infused, leading to complete
remission. Acute GvHD prophylaxis regimen was with cyclosporine, with G-CSF initiated on
day +1. The patient engrafted with an absolute neutrophil count (ANC) greater than 0.5 × 109/
l on day +16. The following day, he developed symptoms of acute GvHD, with temperatures
of up to 40°C, skin rash that on biopsy was consistent with GvHD and severe pulmonary
insufficiency. He was intubated for 2 days and treated with high-dose steroids, with rapid
resolution of symptoms. Platelet engraftment was delayed, with sustained platelets greater
than 30 × 109/l by day +170. He was platelet independent from day +240 and RBC independent
from day +210. Reevaluation of his RBC antibody status revealed a DAT that was only
microscopically positive by day +20 and negative on day +286. Anti-platelet antibodies were
negative on day +115 and day +176. He had no evidence of response with cyclosporine pre-
transplant and no evidence of disease recurrence 2 months after discontinuation of cyclospor-
ine and 4 months after discontinuation of prednisone. At the time of death, the patient was off
all immunosuppression and had complete resolution of his autoimmune disease. However,
the patient died unexpectedly from acute hepatic failure 9 months after transplantation [127].
Itamura et al. reported another case for a 48-year-old female patient with RA [128], who was
subsequently diagnosed as having autoimmune hemolytic anemia (AIHA). Four months after
the diagnosis of AIHA, she suddenly developed hemophagocytic syndrome (HPS) with
disseminated intravascular coagulation (DIC) and Staphylococcus aureus bacteremia. Her HPS
transiently improved after treatment, but relapsed 3 weeks later. Without an immediately
available related adult donor, an unrelated donor CB graft was used for HSCT. The patient had
HLA antibodies against multiple HLA class I antigens; however, the CB unit did not express
HLA antigens reactive to her HLA antibodies and contained sufficient cell dose. HLA type of
the CB graft was A*02:06/A*11:01, B*40:06/B*67:01, DRB1*09:01/DRB1*16:02 and that of the
recipient was A*11:01/A*26:02, B*40:06/B*67:01, DRB1*09:01/DRB1*16:02. Four months after
the onset of HPS, she received a CBT following a conditioning regimen of melphalan (40 
mg/m2/day 2 days), fludarabine (25 mg/m2/day 5 days) and total-body irradiation. Tacrolimus
was used for the prophylaxis of GvHD. Engraftment of neutrophils ANC500 and platelets 20K
occurred on days 14 and 32, respectively. Bone marrow examination on day 60 showed
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complete donor-type chimerism by short tandem repeat-polymerase chain reaction and no
evidence of HPS. EBV-DNA load was under the detectable limit. Post-transplant, the patient
was not only cured for HPS, but also showed marked amelioration of preexisting RA and
AIHA [128].
Others have performed unrelated donor CBT for AD, including at least two pediatric cases of
scleroderma and systemic sclerosis where MaxCell CB products were provided by the
StemCyte CB bank founded by the corresponding author. Both cases were performed at the
same transplant center; however, the attending transplant physician relocated to a different
hospital subsequently and both cases were lost to follow-up [R. Chow, unpublished data].
These CBT cases suggest that allogeneic CBT can potentially be a powerful tool for curing AD
without significant GvHD provided that the cell dose and HLA match is adequate.
In summary, by optimizing transplant conditions and maximizing cell dose through the use
of products manufactured by the MaxCell CB processing technologies, use of double CBT and
direct infusion without post-thaw wash, unrelated CBT has been shown in the largest patient
series of its kind to be capable of producing outstanding clinical outcome for thalassemia major,
with excellent long-term TRM, OS and DFS that rivals or approaches that of related CBT. Such
strategies may be employed to optimize unrelated donor CBT for other nonmalignant
conditions, such as HIV infection or AD. For HIV infection, optimization of cell dose may make
the difference between a HIV-resistant CB graft being eligible for HSCT, especially if in
combination with other grafts. Similarly, cell dose maximization will minimize graft failure
and TRM for CBT of AD. After the establishment of large racially and ethnically diverse CB
banks with MaxCell CB products, further CBT studies of more unrelated patients with
thalassemia, HIV infection and AD will be needed to see whether these hypotheses can be
validated and the strategies can be widely applicable.
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